I want to open this debate by telling Parliament about Sharon Prince, one of my constituents from Dalgety Bay, and her experience of invasive lobular breast cancer. Sharon describes it as “a sneaky cancer”. Having heard her story, I understand why.
In 2021, Sharon received the all-clear following a routine breast screening mammogram. Seven months later, she was diagnosed with breast cancer. She had no lump, no dimpling and none of the symptoms that we are told to look out for. Instead, she experienced a persistent itch and a strange tugging sensation. Initially, she was told that breast cancer was not painful and that it might just be a pulled muscle, but Sharon trusted her gut, and she pushed for further investigation. Even then, her mammogram was clear. It was an ultrasound and subsequent biopsy that finally identified the cancer.
Sharon is here in the gallery today as a survivor, but how different might her story have been had she not persisted in seeking answers? Her experience illustrates why awareness matters. Breast cancer does not always present as a lump, and a clear mammogram should not mean that persistent questions should be dismissed.
Sharon’s story also exposes a wider problem. Invasive lobular breast cancer is the second most common form of breast cancer, accounting for around 15 per cent of diagnoses. Around 22 women are diagnosed with it every day in the United Kingdom, yet, historically, only around 1 per cent of breast cancer research funding has gone towards lobular research. That represents a staggering gap between the scale of the disease and the attention that it has received.
So, what makes lobular different? Unlike many other breast cancers, its cells often grow in a diffuse pattern through breast tissue rather than forming a distinct lump. The loss of a specific protein that helps cells stick together is central to that distinctive behaviour. That biology helps explain why lobular cancer can be difficult to detect through conventional imaging, including mammograms. It can also behave differently after diagnosis, including spreading to different sites and recurring many years after initial treatment.
Those are not minor differences. They matter with regard to how we detect the disease, how we treat it and how we monitor patients over the longer term. Yet, despite those differences, patients can find themselves navigating treatment pathways that have developed around a much broader understanding of breast cancer without sufficient evidence to guide decisions specifically for lobular disease.
Sharon described discovering that as she went through her own treatment. She had to learn about the limitations of the evidence base, the difficulties in monitoring the disease and the questions that the research has yet to answer. Think what that means for somebody who is already dealing with a cancer diagnosis. Think about enduring the treatment and its side effects while knowing that the necessary scientific evidence to guide those decisions remains incomplete.
Sharon’s experience did not end with treatment. She beat the disease and was initially advised that she would receive annual mammograms for five years—mammograms: an approach that she knew was unsuited to the characteristics of this cancer. She questioned whether that follow-up arrangement adequately reflected her particular circumstances, and she once again had to advocate for herself to secure more appropriate screening.
Her experience raises important questions about whether follow-up arrangements sufficiently account for the distinctive characteristics of lobular cancer, including its potential for late recurrence. No patient should have to become their own research advocate simply to ensure that their concerns are heard.
That is why the Lobular Moon Shot Project matters. The proposal is for £20 million over five years to fund eight co-ordinated research work packages, bringing scientists together to investigate the basic biology of lobular cancer. The aim is to understand why this cancer develops and behaves differently, how it spreads, why it recurs years later, and where opportunities might exist to detect it earlier and to develop more effective treatments. It is not simply a request for more research in general; it is a co-ordinated programme that is designed to address the long-standing gap in scientific understanding.
Clinicians have backed that approach. A letter supporting the project, signed by Dr Caroline Michie, a consultant medical oncologist at the Edinburgh Cancer Centre, alongside eight clinical colleagues, highlights the differences in tumour biology, treatment responses and patterns of spread. It makes the case for a better understanding of the disease before more effective drugs can be developed. That professional support matters. The issue is not just the concern of campaigners and patients, as important as those concerns would be. Clinicians are telling us that there is an unmet need.
There is already substantial cross-party support, too. In September, party leaders signed a joint letter to the Prime Minister calling for the £20 million programme to be funded, subject to appropriate scientific proposals, independent peer review and governance.
The question now is how that support translates into action. I welcome the support that has already been expressed by the Scottish Government, and I recognise that funding for discovery science sits at UK level and that Scotland, in effect, is already paying into that fund. However, that makes it so much more important that the Scottish Government uses its influence to press the UK Government to commit to the funding that is required, and that Scottish researchers have a meaningful opportunity to contribute to the programme.
Sharon’s determination helped to secure her diagnosis. She is alive because of it. However, we cannot rely on every patient having the knowledge, confidence and strength to keep pushing when the system around them fails to provide reassurance. Nor should patients and clinicians have to keep asking the same unanswered questions because the research that is needed to answer them has not been adequately funded. We owe it to Sharon, to the thousands of women who have been diagnosed with lobular breast cancer, and to those who will be diagnosed in the years ahead to do better.
The scientific questions have been identified, the researchers are ready to undertake the work, the clinical need is clear, and the political support is there. Let us turn that support into action and call for the Lobular Moon Shot Project to receive the dedicated research funding that it needs.